This meta-analysis aimed to evaluate whether there’s evidence that supports the FDA-mandated warning for increased suicidality risk with antiseizure drug usage among people with epilepsy.
Researchers explored the risk for death in late-onset epilepsy by analyzing data from the prospective Atherosclerosis Risk in Communities (ARIC) study.
Briviact is now indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Primary outcomes were a 50% or greater reduction in seizure frequency and the proportion of patients with complete cessation of seizures by trial conclusion.
Neurology advisor spoke with Charuta Joshi, MBBS regarding the use of the cannabis-based Epidiolex in the treatment of pediatric seizures.
The analysis included 5 antiseizure medications (eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate) evaluated in 17 randomized clinical trials.
A team of researchers sought to determine role of the gut-brain axis as a possible therapeutic target for Theiler murine encephalomyelitis (TMEV) linked seizures.
Study researchers sought to assess how the diagnosis and understanding of focal epilepsy has improved with the inclusion of molecular genetic data in clinical decision making.
This case study detailed a pediatric patient with drug-resistant seizures and early-onset epileptic encephalopathy who carried a GRIN1 variant.
In this case report, a team of investigators highlighted findings in a 50-year-old woman who has been diagnosed with a seizure disorder for 14 years.